SEC Form 4 · accession 0001140361-17-014775

CytomX Therapeutics, Inc. · CTMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Apr 3, 2017

Accepted (ET)

Apr 5, 2017 · 12:18 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001501989

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Apr 3, 2017	M	4,781	$0.945	A	6,760	D
Common Stock^F2	Apr 3, 2017	S	4,781	$16.94	D	1,979	D
Common Stock	Apr 4, 2017	M	4,781	$0.945	A	6,760	D
Common Stock	Apr 4, 2017	S	4,781	$17.50	D	1,979	D
Common Stock^F3	holding	—	—		—	158,737	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4	$0.945	Apr 3, 2017	M	4,781	D	—	Feb 25, 2023	Common Stock	4,781	77,634	D
Stock Option (right to buy)^F4	$0.945	Apr 4, 2017	M	4,781	D	—	Feb 25, 2023	Common Stock	4,781	72,853	D

F1The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.71 to $17.26, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3Held in McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees.
F4100% of the shares subject to the option are fully vested and exercisable.